Doxorubicin is an anthracycline chemotherapy drug widely used in clinic for treating breast, endometrial and gastric cancers, childhood solid tumours, soft tissue sarcomas and aggressive lymphoblastic or myeloblastic leukaemia. 1,2 However, dilated cardiomyopathy and congestive heart failure are frequently reported in patients treated with doxorubicin. Mortality and morbidity are therefore increased when heart failure develops in these patients. 3,4 Dexrazoxane is the only FDA-approved drug that is used to protect against doxorubicin-induced cardiomyopathy, 5 but it carries the risk potential of increasing secondary malignant neoplasms. 6 Betaadrenoceptor blockers, angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers are reported to be effective in preventing anthracycline-induced cardiotoxicity 5 ; however, the reports from different observations are controversial. 7 Therefore, new avenues of exploration are needed to develop better pharmacotherapies and interventions to prevent the cardiotoxicity. 8 It has been reported that several mechanisms are involved in cardiomyopathy induced by doxorubicin, including oxidative stress,